Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Bronchiectasis is a chronic lung condition where parts of the airways are permanently widened, causing mucus buildup, infections, and ongoing inflammation. This study evaluates the long-term use of the SIMEOX medical device at home, combined with remote physiotherapy, to improve quality of life and reduce lung flare-ups in adults with non-cystic fibrosis bronchiectasis. The research compares this approach to enhanced standard care including remote physiotherapy alone. Participants will be randomly assigned to either standard care with remote physiotherapy or to use the SIMEOX device daily at home alongside remote physiotherapy. Remote physiotherapy sessions occur once a month for the first three months and then every three months. The study spans an average of 24 months to assess the effects of adding the SIMEOX device to usual care. During the study, participants will complete quality of life questionnaires and undergo lung function tests at 6, 12, and 24 months. The main outcomes measured include the yearly rate of lung exacerbations and changes in quality of life scores. Researchers will also track hospitalizations, treatment compliance, adverse events, and lung function changes. The long follow-up aims to evaluate the sustained impact of the device and physiotherapy on participants respiratory health.
Actively Recruiting
Researchers are evaluating the long-term reliability and performance of cardiac rhythm products marketed by Medtronic. This observational study focuses on devices such as leads, implantable pulse generators, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices used for conditions like arrhythmia, bradycardia, heart failure, and sinus tachycardia. The study aims to analyze product survival probabilities and monitor lead-related complications over time. Participants include individuals who have received or will receive Medtronic market-released cardiac devices for pacing, sensing, or defibrillation. The study includes products implanted as part of routine care or participants from prior qualifying studies. Data is collected from the time of implantation and continues until the device is removed from service, the patient exits the study, or passes away. Enrollment criteria also require consent for access to health information. During the study, participants device performance is monitored through follow-up data collection. Researchers assess complications related to the implanted leads and track device status over long periods, potentially spanning several years. The study does not involve additional treatments but relies on routine clinical follow-up and health information review. The total duration extends up to December 2040, allowing comprehensive long-term evaluation of device performance.
Actively Recruiting
This observational registry study is designed to continuously evaluate and periodically report on the safety and effectiveness of Medtronic market-released medical products. It aims to support patients, hospitals, clinicians, regulatory bodies, payers, and the medical industry by streamlining clinical surveillance and enhancing performance assessment with minimal burden. Participants include patients who have received or are intended to receive an eligible Medtronic product. The registry collects data related to various conditions such as cardiac rhythm disorders, neurological disorders, cardiovascular disorders, and several others, with ongoing monitoring every 6 to 12 months depending on the therapy. During the study, participants provide consent and data is collected during routine care and follow-up visits. The research team reviews safety and effectiveness outcomes regularly to understand product performance over time. The study is planned to continue until January 2040, allowing for long-term monitoring and reporting.
Actively Recruiting
This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.
Actively Recruiting
Researchers are evaluating the effects of nucresiran compared to placebo in patients with transthyretin amyloidosis with cardiomyopathy, a condition involving abnormal protein buildup in the heart. This study aims to assess whether nucresiran can reduce deaths from any cause and cardiovascular events, and also improve patient-reported health status and quality of life. The trial is a Phase 3, randomized, double-blind study focused on treatment outcomes. Participants will be randomly assigned to receive either nucresiran 300 mg or a placebo, both given as subcutaneous injections every six months during the double-blind period lasting up to 32 months with a maximum of 5 years. After this period, all participants enter an open-label extension where everyone receives nucresiran 300 mg every six months. Patients may continue some background therapies as decided by their investigators. Throughout the study, participants will be monitored for mortality and cardiovascular events, including hospitalizations and urgent heart failure visits. Health status and quality of life will be assessed using questionnaires. Safety and efficacy are evaluated through regular assessments during the double-blind phase and ongoing follow-up during the extension. The total study duration extends up to approximately 7 years, including follow-up after the main treatment period.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.